acute T lymphpblastic leukemia/lymphoma
Conditions
Interventions
The study group:Venetoclax combined with HAG regimen
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
14 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Before enrollment, a diagnosis of newly diagnosed T-cell acute leukemia/lymphoma.The diagnostic criteria refer to the 2022 WHO classification; 2.Age = 14 years,<75 years; 3.Clincally diagnosed as relapsed or refractory T-ALL/LBL; 4.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; 5.Expected survival time = 2 months; 6.No organ dysfunction that would restrict the use of this protocol during the screening period; 7.Understand the study and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Patients with known central nervous system (CNS) involvement of T-ALL/LBL; 2.Diseases with abnormal heart, lung, liver, kidney, or other organ functions that may limit the patient's participation in this trial (including but not limited to severe infections, uncontrolled diabetes, severe heart failure or angina, active pulmonary tuberculosis, asthma, COPD, bronchiectasis, etc.); 3.Cardiac ultrasound LVEF 1.5 ULN (upper limit of normal); ALT or AST > 2.5 ULN; serum creatinine > 1.5 ULN; 6.Known HIV infection; 7.Conditions affecting the use of the study drug as assessed by the investigator; 8.Inability to understand or comply with the study protocol;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR/CRi; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Event free survival;MRD;Adverse event; | — |
Countries
China
Contacts
Public ContactJie Jin
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed